A D V E R T I S E M E N T F E A T U R E

A D V E R T I S E R R E TA I N S S O L E R E S P O N S I B I L I T Y F O R C O N T E N T

ImmunoPrecise Antibodies Ltd.www.immunoprecise.com

Single source provider of full-servicetherapeutic antibody developmentImmunoPrecise offers a comprehensive suite of solutions to rapidly deliver high-performing therapeutic antibodies.

ImmunoPrecise Antibodies (IPA) is an innovation-driven, technology platform company thatsupports its pharmaceutical and biotechnologycompany partners in their quest to discover anddevelop novel, therapeutic antibodies against allclasses of disease targets.

IPA aims to transform the conventional,multi-vendor, product development model bybringing advanced high-throughput, data-driventechnologies to its partners. IPA incorporatesthe advantages of diverse antibody repertoireswith its therapeutic antibody discovery suiteof technologies, to exploit antibodies of broadepitope coverage, multiple antibody formats,valency and size, and to discover antibodiesagainst multiple/rare epitopes.

Operating from state-of-the-art laboratorieslocated in Victoria, British Columbia, and in Ossand Utrecht in the Netherlands, the companybrings resourceful solutions, adaptableapproaches, and insightful collaboration toevery program. IPA’s single-source model, fastturn-around, and >95% success rate can greatlyaccelerate the critically important research ofits global partners (Fig. 1). The expertise ofIPA’s dedicated technical team assures optimalwork plans are followed for the discovery anddevelopment of custom, high-performingtherapeutic antibodies.

A comprehensive suite ofantibody discovery servicesImmunoPrecise’s broad range of capabilities canseamlessly take a program from concept to (pre)clinic and allows for discovery in a wide rangeof species and strains that include rabbit, llama,human, and wild-type and transgenic mouse, ratand chicken models.

Some of the most in-demand technologiesare IPA’s unique immunization methods, theproprietary B cell Select and DeepDisplaydiscovery platforms, and robust, efficient antibodyengineering and optimization protocols.• Immunization technologies utilized include

three genetic immunization options—genegun, dermal tattooing, and hydrodynamic tailvein (HTV) injection—as well as whole cellimmunization (ModiVacc) and an acceleratedRapidPrime program.

• B cell Select allows the screening of an animal’sentire immune repertoire and the selection ofa desired antibody directly from B cells forearlier hit identification from a more diversepanel of antibodies compared with traditionaltechnologies. Screening the entire population

of B cells optimizes throughput and successrates while maintaining native heavy and lightchain pairings.

• DeepDisplay is based upon the selectionof antigen-specific recombinant antibodyfragments from custom immune libraries frommultiple species in a single-chain variablefragment (scFv) or single-domain antibody(VHH) format. Partners also have access to theIPA’s proprietary in-house disease and naïvehuman or llama phage libraries.

• ImmunoPrecise’s affinity maturation service canimprove antibody affinities significantly, whilethe humanization approach results in antibodieswith retained affinity and specificity.

Additional, complementary services that roundout the company’s end-to-end service modelinclude protein expression and purificationusing the proprietary rPEx platform, affinitymaturation, antibody characterization andoptimization, developability studies, stable cellline development and cryopreservation servicesand storage.

Personalized antibody developmentWith more than 30 years of antibody developmentand protein manufacturing experience, andthousands of successful projects, IPA understandsthe importance of strong project management andcommunication skills. Skilled scientists developcustom, tailored programs to meet client needsand budgets, while designated project managersdirectly communicate and share data with thepartner using secure, cloud-based platformswith 24/7 access. “Our infrastructure andexperience in antibody discovery and proteinmanufacturing together with our streamlinedproject management enables us to help ensure ourpartners’ success, no matter how challenging thedisease or target,” said Stefan Lang, CBO of IPA.

Partnering: leveraging the power ofIPA services for antibody discoveryTalem Therapeutics, an ImmunoPrecise company,is focused on the discovery and developmentof next-generation, fully-human, monoclonaltherapeutic antibodies to target multiple diseaseindications. Talem aims to accelerate novel,high-value, therapeutic antibody treatmentsto the clinic, by leveraging direct access toIPA’s proprietary antibody discovery platformsand innovative technologies to rapidly developproducts with greater chances of success. Talemhas created a diverse internal pipeline and isopen for flexible partnership and out-licensingopportunities.

Fig. 1 | ImmunoPrecise’s single-source suite of solutions. IPA’s single-source, open-access biologicstechnology platform offers end-to-end solutions, empowering partners to discover and develop biologicsfrom concept to clinical lead.

Stefan Lang, CBOImmunoPrecise Antibodies Ltd.Victoria, BC, CanadaTel: +1-250-483-0308Email: solutions@immunoprecise.com

CON

TACT

“Our infrastructure andexperience in antibody

discovery and proteinmanufacturing together withour streamlined projectmanagement enables us tohelp ensure our partners’success, no matter howchallenging the disease ortarget

Stefan Lang, CBO,ImmunoPrecise Antibodies

www.nature.com/biopharmdeal | September 2021 | B35